Patent expiry of key blockbuster drugs good news for generics manufacturers, says F&S

The global generic pharmaceuticals market is likely to witness strong growth in the next few years owing to the patent expiration of key blockbuster drugs and the judicious cost containment efforts of governments and health care service providers worldwide. At the same time, the balance in terms of health care expenditure and sales revenue is poised to shift from developed to emerging markets such as India, China, Brazil, Russia, Turkey and South Korea, as huge potential still remains untapped in these countries.

A new analysis from Frost & Sullivan, titled Generic Pharmaceuticals Market - A Global Analysis, finds that the market earned revenues of $123.85 billion in 2010 and estimates this to reach $231.00 billion in 2017 at a compound annual growth rate (CAGR) of 9.29% from 2011-2018. Regions covered in the research include the USA, Europe (Germany, the UK, France, Spain, and Italy) and Asia (India and China).

$150 billion of drugs due to lose patent protection between 2010 and 2017